Edition:
India

Pulse Biosciences Inc (PLSE.OQ)

PLSE.OQ on NASDAQ Stock Exchange Capital Market

26.08USD
2:29am IST
Change (% chg)

$0.14 (+0.54%)
Prev Close
$25.94
Open
$25.73
Day's High
$27.37
Day's Low
$25.73
Volume
50,811
Avg. Vol
85,555
52-wk High
$39.50
52-wk Low
$5.21

Select another date:

Wed, Nov 8 2017

BRIEF-Pulse Biosciences Inc reports qtrly loss per share $‍0.52​

* Pulse Biosciences Inc - qtrly loss per share $‍0.52​ Source text for Eikon: (http://bit.ly/2AiM76K) Further company coverage:

BRIEF-Pulse Biosciences announces transition of board of directors

* Pulse Biosciences announces transition of board of directors, extends appreciation to retiring members and welcomes new board members

BRIEF-Pulse Biosciences announces $30 million private placement

* Pulse Biosciences - ‍entered into stock purchase agreement for purchase of 2 million shares of company's common stock at a price of $15.02 per share​ Source text for Eikon: Further company coverage:

BRIEF-Pulse Biosciences announces withdrawal and planned resubmission of 510(k) application for the PulseTxTM System

* Pulse Biosciences Inc - "‍remain confident" in ability to obtain a 510(k) clearance for PulseTx System and more broadly for Nano-Pulse Stimulation​

BRIEF-Pulse Biosciences qtrly loss per share $ 0.43

* Pulse Biosciences Inc - cash, cash equivalents, and investments totaled $15.4 million at June 30, 2017, compared to $16.4 million at December 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Pulse Biosciences files for offering of 1.7 mln shares of common stock by selling stockholders

* Pulse biosciences inc files for offering of 1.7 million shares of common stock by selling stockholders - sec filing Source text for Eikon: Further company coverage:

BRIEF-Pulse Biosciences files for mixed shelf of up to $150 mln

* Files for mixed shelf of up to $150 million - SEC filing Source text: (http://bit.ly/2svQ7MC) Further company coverage:

BRIEF-‍Pulse Biosciences announces treatment of first patient

* ‍Pulse Biosciences-treatment of first patient in study to evaluate safety, efficacy of novel nano-pulse stimulation technology for seborrheic keratosis lesions​ Source text for Eikon: Further company coverage:

Select another date: